Overview

Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.

Status:
Completed
Trial end date:
2020-03-27
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor underactivity patients with overactive bladder.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Criteria
Key Inclusion Criteria:

- To have Lower Urinary Tract Symptoms for at least 12 weeks prior to study entry

- To have at least 1 urinary urgency episodes per day, and diurnal urinary frequency of
8 or more per day.

- To meet the detrusor underactivity criteria by urodynamic study

Key Exclusion Criteria:

- Neurogenic bladder by the central nervous system diseases.

- StageIII or more cystocele of pelvic organ prolapse quantification system (women)

- Prostate volume ≥30mL (Men)

- Any symptoms of Urinary tract infection (UTI)